The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. [electronic resource]
Producer: 20111003Description: 389-98 p. digitalISSN:- 1432-0843
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Apoptosis -- drug effects
- Camptothecin -- administration & dosage
- Cell Proliferation -- drug effects
- Colonic Neoplasms -- drug therapy
- Drug Synergism
- Female
- HCT116 Cells
- HT29 Cells
- Histone Deacetylase Inhibitors -- administration & dosage
- Humans
- Hydroxamic Acids -- administration & dosage
- Irinotecan
- Mice
- Mice, Nude
- Prodrugs -- administration & dosage
- Random Allocation
- Sulfonamides
- Topoisomerase I Inhibitors -- administration & dosage
- Tumor Burden -- drug effects
- Whole Body Imaging
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.